Table 3.
Target mRNA levels in 2 NSCLC xenografts after bevacizumab treatment
| |
NSCLC#3 |
NSCLC#5 |
|||||
|---|---|---|---|---|---|---|---|
| Control (n=5) | After bevacizumab reatment (n=5) | p-value 1 | Control (n=5) | After bevacizumab treatment (n=5) | p-value 1 | ||
|
PECAM1/CD31
mRNA |
Human
|
18.1 (7.34-43.1) |
57.6 (31.8-64.2) |
<0.05 |
2.38 (0.00-9.21) |
6.70 (2.41-17.1) NS |
|
| |
Mouse
|
863 (686-1790) |
578 (483-847) |
<0.05 |
2 334 (1 538-4 363) |
856 (699-980) |
<0.05 |
|
ENG/CD105
mRNA |
Human
|
29.1 (3.59-47.2) |
38.2 (15.1-71.4) |
NS |
57.64 (38.8-90.86) |
57.50 (47.2 - 84.4) |
NS |
| |
Mouse
|
619 (580-1098) |
414 (328-619) |
<0.05 |
1 519 (1120-1813) |
821 (610-860) |
<0.05 |
|
FLT1/VEGFR1
mRNA |
Human
|
59.6 (56.7-90.6) |
88.9 (62.3-118) |
NS |
3.84 (0.00-24.8) |
9.11 (3.87-20.3) |
NS |
| |
Mouse
|
589 (470-909) |
274 (212-362) |
<0.05 |
938 (633-1163) |
305 (216-344) |
<0.05 |
|
KDR/VEGFR2
mRNA |
Human
|
507 (361-622) |
545 (488-643) |
NS |
220 (140-274) |
574 (213-834) |
NS |
| |
Mouse
|
466 (386-800) |
204 (196-298) |
<0.05 |
1 175 (698-1 211) |
328 (316-349) |
<0.05 |
|
VEGFA
mRNA |
Human
|
20 503 (19162-24600) |
32 160 (30 331-35 680) |
<0.05 |
11 984 (5 368-13 961) |
12 235 (7 088-14 042) |
NS |
| Mouse | 160 (119-495) | 307 (184-614) | NS | 262 (170-680) | 267 (240-360) | NS | |
Results are expressed as normalized N-fold differences in target gene expression relative to the ‘Total-TBP’ expression. These Ntarget values of the tumor samples were normalized such that the value for the ’basal mRNA level‘ (Ct = 35) was 1Target mRNA levels that were total absence or very low (Ct > 38) in tumor samples were scored ‘0’ for non expressed.
Median and range in () are given for each gene in the different experimental conditions. 1Mann Whitney Test; NS, not significant; in bold, significant.